A Clinical Introduction to Psychedelic Therapies
Get immediate access to all course materials and begin your journey today.
Enroll in Masterclass - $250Enrollment takes under 2 minutes and you get immediate next-step instructions.
Training Outcomes
We track outcomes across cohorts. Here's what the numbers say about expanding therapeutic horizons.
Exit surveys conducted 30 days post-certification. Response rate: 89%. Dropout analysis shows highest attrition occurs during Phase 1 screening module (months 1-3). Post-certification support includes 12 supervised integration calls over 6 months.
Evidence base for Psilocybin in therapeutic contexts
The following peer-reviewed research supports the therapeutic application of Psilocybin. These studies inform our curriculum and underscore the importance of evidence-based practice in psychedelic-assisted therapy.
Goodwin, G.M. et al. • 2025 • Journal of Clinical Psychiatry
Finding52-week observational follow-up: a single 25 mg COMP360 psilocybin dose showed longer-term antidepressant effects than lower doses, with response durability across a year.
View on PubMed(opens in a new tab)Raison, C.L. et al. • 2023 • JAMA
FindingLandmark randomized trial in JAMA: a single 25 mg psilocybin session with psychotherapy produced rapid, sustained antidepressant effects.
View on PubMed(opens in a new tab)Rosenblat, J.D. et al. • 2024 • Med
FindingIndependent randomized trial replicating single-dose psilocybin efficacy in treatment-resistant depression — evidence beyond the originating group.
View on PubMed(opens in a new tab)Agin-Liebes, G.I. et al. • 2020 • Journal of Psychopharmacology
FindingFollow-up data: anxiety and depression reductions after psilocybin-assisted psychotherapy persisted at long-term follow-up in patients with life-threatening cancer.
View on PubMed(opens in a new tab)Lebedev, A.V. et al. • 2015 • Human Brain Mapping
FindingNeuroimaging study linking psilocybin-induced ego dissolution to disorganized activity in association networks — the mechanistic basis of the experience.
View on PubMed(opens in a new tab)Bukovsky, D. et al. • 2025 • Progress in Neuro-Psychopharmacology & Biological Psychiatry
FindingSystematic review of adverse-event handling across psilocybin trials: what safe protocols screen for and how they manage events.
View on PubMed(opens in a new tab)6 peer-reviewed studies curated from PubMed and clinical trial registries.
Browse the full research databaseParticipants gain a clear map of where psychedelic therapy stands today, legally and clinically, without abandoning professional rigor.
Start with legal status, regulatory shifts, and the historical context that shapes current psychedelic practice.
Review ketamine, psilocybin, and MDMA through mechanisms of action, therapeutic potential, and practical implementation realities.
Emphasis remains on preparation, screening, safety awareness, and integration support rather than intensity-driven narratives.
Close with expert lectures, curated resources, and practical next steps for continued education within scope.
A structured pathway designed to take you from foundational science to advanced facilitation mastery.
Foundational orientation to the field and its current legal and cultural status. Participants gain clarity about where psychedelic therapy stands today legally and culturally.
A blend of clinical precision and experiential wisdom.
The Visionary
Founder of Mindscape Psychedelic Institute. He bridges the gap between the street and the clinic. A master facilitator of 5-MeO-DMT who understands that trauma-informed care is the only care that matters.
The Integrator
She blends the clinical world of Marriage and Family Therapy with the depth of Internal Family Systems (IFS) and Ketamine. She knows how to hold space for the parts of us that are most afraid.
The Psychiatrist
Chief Medical Officer. Board-certified. He has worked from Afghanistan to the Menninger Clinic and brings medical credibility necessary to legitimize this work in clinical settings.
The Activist-Healer
A licensed psychologist with Indigenous heritage who helped decriminalize nature in DC and Denver. He reminds us that this medicine is old, even when the frameworks are new.
Why Mindscape
Not the easiest path. The one that actually prepares you.
Every graduate evaluated on ethical competency, not just attendance.
Built on clinical best practices, not weekend workshop shortcuts.
Real container, real accountability, real professional standards.
What graduates say
Here's what people say after completing our programs.
“The depth of this training surprised me. It's not just theory — you're pushed to actually embody the material. I came out a fundamentally different facilitator.”
Dr. Sarah M.
Clinical Psychologist
5-MeO-DMT Facilitation
“I'd done three other psychedelic trainings before this. None of them came close to the rigor and ethical grounding here. This is what the field needs.”
James T.
Integration Coach
5-MeO-DMT Facilitation
“The interview process alone told me this program takes standards seriously. The curriculum delivered exactly what was promised — no fluff, no spiritual bypassing.”
Maria L.
LMFT, Private Practice
Ketamine-Assisted Therapy
“What sets Mindscape apart is the accountability. You're not just watching videos — you're being evaluated on actual competency. That matters when you're working with people in altered states.”
David R.
Harm Reduction Specialist
5-MeO-DMT Facilitation
“I was skeptical about another certification program. But the curriculum structure, the live components, and the ethical framework are genuinely best-in-class.”
Dr. Rachel K.
Psychiatrist
Ketamine-Assisted Therapy
“The masterclass format was perfect for my schedule. Deep content, well-organized, and immediately applicable to my practice. Worth every penny.”
Alex P.
Licensed Therapist
MDMA Masterclass
Have questions? Chat with us!